Intellectual Product
Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B
Obesity, LX9851, lexicon, Mechanism (attribute)
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey
Manufacture, EU, Surveys, Financial cost, Fear (Mental Process), Bio
FDAs policy, communications staff likely to be among agencys 3,500 staff cuts
Policy, Communication, Staff, United States Food and Drug Administration, CHARGE Syndrome
Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
DOGE Reverses Course on FDA Facility Closures, Including Major St. Louis Quality Lab
DOGE, FDA, lease terminations, St. Louis, drug quality lab, cost-cutting, reversal
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent